Molecular imaging in oncology: Current impact and future directions
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Recent progress in functionalized and targeted polymersomes and chimeric polymeric nanotheranostic platforms for cancer therapy
M Beygi, F Oroojalian, SS Hosseini… - Progress in Materials …, 2023 - Elsevier
The majority of advances in cancer therapy have been achieved based on developments in
public awareness, as well as novel diagnostic and therapeutic modalities. Treatment …
public awareness, as well as novel diagnostic and therapeutic modalities. Treatment …
[PDF][PDF] SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors
Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy
MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …
guidelines, a systematic review of evidence was performed. We followed the Preferred …
Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
H Ilhan, S Lindner, A Todica, CC Cyran, R Tiling… - European journal of …, 2020 - Springer
Abstract Introduction PET/CT using 68 Ga-labeled somatostatin analogs (SSA) targeting
somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine …
somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine …
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with …
C Ortega, RKS Wong, J Schaefferkoetter… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The aim of this study was to determine whether quantitative PET parameters on baseline
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of …
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of …
The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker
Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …
a result of the growing research interest in personalized medicine to improve diagnostic …
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
MN Becx, NS Minczeles, T Brabander, WW de Herder… - Cancers, 2022 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
[HTML][HTML] Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
G di Santo, G Santo, A Sviridenko, I Virgolini - Theranostics, 2024 - ncbi.nlm.nih.gov
A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
Somatostatin receptor imaging and theranostics: current practice and future prospects
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …